-
Something wrong with this record ?
ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas
L. Sommerova, E. Ondrouskova, A. Martisova, V. Zoumpourlis, S. Galtsidis, R. Hrstka,
Language English Country Switzerland
Document type Journal Article
Grant support
GACR 19-02014S
Grantová Agentura České Republiky
MMCI, 00209805
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
Epithelial-mesenchymal transition (EMT) is a process involved not only in morphogenesis and embryonic development, but also in cancer progression, whereby tumor cells obtain a more aggressive metastatic phenotype. Anterior gradient protein 2 (AGR2) maintains the epithelial phenotype and blocks the induction of EMT, thus playing an undeniable role in tumor progression. However, the mechanism through which AGR2 expression is regulated, not only during EMT, but also in the early stages of cancer development, remains to be elucidated. In the present study, we show an inverse correlation of AGR2 with ZEB1 (zinc finger enhancer binding protein, δEF1) that was verified by analysis of several independent clinical data sets of lung adenocarcinomas. We also identified the ZEB1 binding site within the AGR2 promoter region and confirmed AGR2 as a novel molecular target of ZEB1. The overexpression of ZEB1 decreased the promoter activity of the AGR2 gene, which resulted in reduced AGR2 protein level and the acquisition of a more invasive phenotype of these lung cancer cells. Conversely, silencing of ZEB1 led not only to increased levels of AGR2 protein, but also attenuated the invasiveness of tumor cells. The AGR2 knockout, vice versa, increased ZEB1 expression, indicating that the ZEB1/AGR2 regulatory axis may function in a double negative feedback loop. In conclusion, we revealed for the first time that ZEB1 regulates AGR2 at the transcriptional level, while AGR2 presence contributes to ZEB1 mRNA degradation. Thus, our data identify a new regulatory mechanism between AGR2 and ZEB1, two rivals in the EMT process, tightly associated with the development of metastasis.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019031
- 003
- CZ-PrNML
- 005
- 20201123124605.0
- 007
- ta
- 008
- 201103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers12061614 $2 doi
- 035 __
- $a (PubMed)32570918
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Sommerova, Lucia $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.
- 245 10
- $a ZEB1/miR-200c/AGR2: A New Regulatory Loop Modulating the Epithelial-Mesenchymal Transition in Lung Adenocarcinomas / $c L. Sommerova, E. Ondrouskova, A. Martisova, V. Zoumpourlis, S. Galtsidis, R. Hrstka,
- 520 9_
- $a Epithelial-mesenchymal transition (EMT) is a process involved not only in morphogenesis and embryonic development, but also in cancer progression, whereby tumor cells obtain a more aggressive metastatic phenotype. Anterior gradient protein 2 (AGR2) maintains the epithelial phenotype and blocks the induction of EMT, thus playing an undeniable role in tumor progression. However, the mechanism through which AGR2 expression is regulated, not only during EMT, but also in the early stages of cancer development, remains to be elucidated. In the present study, we show an inverse correlation of AGR2 with ZEB1 (zinc finger enhancer binding protein, δEF1) that was verified by analysis of several independent clinical data sets of lung adenocarcinomas. We also identified the ZEB1 binding site within the AGR2 promoter region and confirmed AGR2 as a novel molecular target of ZEB1. The overexpression of ZEB1 decreased the promoter activity of the AGR2 gene, which resulted in reduced AGR2 protein level and the acquisition of a more invasive phenotype of these lung cancer cells. Conversely, silencing of ZEB1 led not only to increased levels of AGR2 protein, but also attenuated the invasiveness of tumor cells. The AGR2 knockout, vice versa, increased ZEB1 expression, indicating that the ZEB1/AGR2 regulatory axis may function in a double negative feedback loop. In conclusion, we revealed for the first time that ZEB1 regulates AGR2 at the transcriptional level, while AGR2 presence contributes to ZEB1 mRNA degradation. Thus, our data identify a new regulatory mechanism between AGR2 and ZEB1, two rivals in the EMT process, tightly associated with the development of metastasis.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ondrouskova, Eva $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.
- 700 1_
- $a Martisova, Andrea $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.
- 700 1_
- $a Zoumpourlis, Vassilis $u Biomedical Applications Unit, Institute of Biology, Medicinal Chemistry & Biotechnology, NHRF 48 Vassileos Constantinou Ave., 11635 Athens, Greece.
- 700 1_
- $a Galtsidis, Sotirios $u Life Sciences Research Unit, University of Luxembourg, Campus Belval, Biotech 1, Avenue des Hauts Fourneaux, L-4362 Esch-sur-Alzette, Luxembourg.
- 700 1_
- $a Hrstka, Roman $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 6 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32570918 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123124604 $b ABA008
- 999 __
- $a ind $b bmc $g 1585811 $s 1109229
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 12 $c 6 $e 20200618 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a GACR 19-02014S $p Grantová Agentura České Republiky
- GRA __
- $a MMCI, 00209805 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $a Pubmed-20201103